Grant: Planning and Dissemination Grant - Institute Community Support
University of British Columbia
$10,000.00
Towards Improving Screening of Retinal Toxicity of Hydroxychloroquine in patients with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA).
EF 2018-19
Résumé
Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are diseases of the immune system that affect many parts of the body (e.g., joints, heart, eyes, skin), dramatically altering quality of life, and can result in other medical complications and untimely death. A drug called hydroxychloroquine (HCQ) is commonly used to treat SLE and RA. Many studies have highlighted benefits of HCQ, including less severe disease, fewer complications (e.g., blood clots, problems with pregnancy or kidneys), and longer life. Stopping HCQ can lead to episodes of more severe disease and premature death. Although HCQ is typically safe and easy to take, a serious long-term side-effect is eye damage that could cause vision loss. The risk of vision loss in HCQ users can be prevented by routine screening, however, a recent study by our team found that only a small percentage (40%) of people using HCQ had received annual screening as per current guidelines. Therefore, it is important to identify the barriers to guideline-recommended screening and develop strategies to improve screening for HCQ retinal toxicity that lead to vision loss.
Programme
Planning and Dissemination Grant - Institute Community Support
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
404423
Name
Avina-Zubieta Juan A
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Clinical
Prcname2
Planning and Dissemination - IMHA
Projecttitle
Towards Improving Screening of Retinal Toxicity of Hydroxychloroquine in patients with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA).
Programtype2
Miscellaneous Programs
Orgnameinp2
University of British Columbia
Cihramount2
$10,000
Cihrequipment2
$0
Programname2
Planning and Dissemination Grant - Institute Community Support
Keyworddelim
Ophthalmology; Rheumatology
Abstract
Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are diseases of the immune system that affect many parts of the body (e.g., joints, heart, eyes, skin), dramatically altering quality of life, and can result in other medical complications and untimely death. A drug called hydroxychloroquine (HCQ) is commonly used to treat SLE and RA. Many studies have highlighted benefits of HCQ, including less severe disease, fewer complications (e.g., blood clots, problems with pregnancy or kidneys), and longer life. Stopping HCQ can lead to episodes of more severe disease and premature death. Although HCQ is typically safe and easy to take, a serious long-term side-effect is eye damage that could cause vision loss. The risk of vision loss in HCQ users can be prevented by routine screening, however, a recent study by our team found that only a small percentage (40%) of people using HCQ had received annual screening as per current guidelines. Therefore, it is important to identify the barriers to guideline-recommended screening and develop strategies to improve screening for HCQ retinal toxicity that lead to vision loss.
Competitiondate
201903
Approvedterm2
1 yr 0 mth
Pinamesdelim
Avina-Zubieta, Juan A
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Musculoskel Hlth &Arth~ $10,000~ $0~